Publications by authors named "G Gigante"

Background: Novel circulating markers for the non-invasive staging of chronic liver disease (CLD) are in high demand. Although underutilized, extracellular matrix (ECM) components offer significant diagnostic potential. This study evaluates ECM-related markers in hepatitis C virus (HCV)-positive patients across varying fibrosis stages.

View Article and Find Full Text PDF

Background: There are few studies investigating patients' needs in healthcare focusing on disease severity and psychological characteristics of elderly heart failure (HF) patients with multimorbidity, specifically addressed by a care manager (CM).

Aims: To explore the role of a CM dealing with elderly multimorbid HF patients' needs/preferences according to NYHA class, ejection fraction, psychological/psychosomatic distress and quality of life (QoL), utilizing a Blended Collaborative Care (BCC) approach (ESCAPE; Grant agreement No 945377).

Methods: Cue cards, self-reported questionnaires, and a semi-structured interview were used to collect data.

View Article and Find Full Text PDF

Background: SMYD3 has been found implicated in cancer progression. Its overexpression correlates with cancer growth and invasion, especially in gastrointestinal tumors. SMYD3 transactivates multiple oncogenic mechanisms, favoring cancer development.

View Article and Find Full Text PDF

Psychological characterization of patients affected by Inflammatory Bowel Disease (IBD) focuses on comorbidity with psychiatric disorders, somatization or alexithymia. Whereas IBD patients had higher risk of stable anxiety and depression for many years after the diagnosis of the disease, there is a lack of studies reporting a comprehensive psychosomatic assessment addressing factors of disease vulnerability, also in the long-term. The objective of this investigation is to fill this gap in the current literature.

View Article and Find Full Text PDF
Article Synopsis
  • The SUPREME 2.0 study looked at how well the medicine secukinumab works for people with severe skin condition psoriasis over a long time (42 months).
  • Out of 415 patients from a previous study, 297 continued taking secukinumab, and most of them were doing great with their treatment.
  • The study found that the patients’ skin improved a lot, and the medicine was safe, matching what we already knew about it.
View Article and Find Full Text PDF